After watching video from Quest, I communicated th
Post# of 153903
(Total Views: 904)
Posted On: 05/16/2021 12:56:19 AM
After watching video from Quest, I communicated this to my representative. Please use it as a template to send a letter to your representatives.
This is link to form to contact your representative:
https://www.house.gov/representatives/find-yo...esentative
What I sent:
Please view this short video regarding a Covid-19 treatment that is being ignored by the FDA likely due to protecting the interest of "Big Pharma".
https://www.questclinical.com/video-hope-for-...l-covid-19
I and many other concerned physicians have written Dr. Janet Woodcock but have received minimal response except that she cannot discuss details regarding her agency's failure to act.
Patients can receive this therapeutic through an onerous application process for EIND. My own colleagues are hesitant to adopt this process due to its time consuming nature (onerous application, delay in obtaining the therapeutic during which time the patient may pass, lengthy discussions regarding use of investigational products with patient and family, perceived medico-legal risk of using investigational products in a critically ill patients who already have a high mortality rate, etc). Instead they are forced to use inappropriate, costly and ineffective treatments such as remdesivir in critically ill patients because it is FDA approved. Remdesivir is an anti-viral medication and therefore has no beneficial effect in critically ill patients who have moved from the viral phase (early) to the immunologic phase (no virus around, but cytokine storm causing ARDS and multi-system failure). If my ICU colleagues fail to use this knowingly inappropriate/ineffective drug, then they risk legal ramifications after the demise of these high risk patients. Billions have been spent on remdesivir and hundreds of thousands have died due to this dynamic. Remdesivir has never shown any mortality benefit. In one study of less sick patients it showed slightly decreased length of hospital stay. Even that benefit was refuted by a much larger study/meta-analysis quoted by the World Health Organization. Tragically, our FDA's failure to grant EUA to Leronlimab (which has shown a statistically significant mortality benefit) has delayed its acceptance in other countries where Covid-19 is rampant. Cytodyn is arranging studies in these countries, but hundreds of thousands will likely die during the time it takes to complete them. Please be the voice that represents our efforts to do what is right to expedite approval of this live saving therapeutic.
This is link to form to contact your representative:
https://www.house.gov/representatives/find-yo...esentative
What I sent:
Please view this short video regarding a Covid-19 treatment that is being ignored by the FDA likely due to protecting the interest of "Big Pharma".
https://www.questclinical.com/video-hope-for-...l-covid-19
I and many other concerned physicians have written Dr. Janet Woodcock but have received minimal response except that she cannot discuss details regarding her agency's failure to act.
Patients can receive this therapeutic through an onerous application process for EIND. My own colleagues are hesitant to adopt this process due to its time consuming nature (onerous application, delay in obtaining the therapeutic during which time the patient may pass, lengthy discussions regarding use of investigational products with patient and family, perceived medico-legal risk of using investigational products in a critically ill patients who already have a high mortality rate, etc). Instead they are forced to use inappropriate, costly and ineffective treatments such as remdesivir in critically ill patients because it is FDA approved. Remdesivir is an anti-viral medication and therefore has no beneficial effect in critically ill patients who have moved from the viral phase (early) to the immunologic phase (no virus around, but cytokine storm causing ARDS and multi-system failure). If my ICU colleagues fail to use this knowingly inappropriate/ineffective drug, then they risk legal ramifications after the demise of these high risk patients. Billions have been spent on remdesivir and hundreds of thousands have died due to this dynamic. Remdesivir has never shown any mortality benefit. In one study of less sick patients it showed slightly decreased length of hospital stay. Even that benefit was refuted by a much larger study/meta-analysis quoted by the World Health Organization. Tragically, our FDA's failure to grant EUA to Leronlimab (which has shown a statistically significant mortality benefit) has delayed its acceptance in other countries where Covid-19 is rampant. Cytodyn is arranging studies in these countries, but hundreds of thousands will likely die during the time it takes to complete them. Please be the voice that represents our efforts to do what is right to expedite approval of this live saving therapeutic.
(23)
(0)